open access

Online first
Original article
Published online: 2021-06-14
Get Citation

Long-term clinical follow-up of the resorbable magnesium scaffolds in acute coronary syndrome patients

Adrian Włodarczak, Magdalena Łanocha, Maciej Lesiak, Johan Benett, Marek Szudrowicz, Artur Jastrzębski, Maciej Pęcherzewski, Jan Jakub Kulczycki, Łukasz Furtan, Karol Turkiewicz, Andrzej Korda
DOI: 10.33963/KP.a2021.0035
·
Pubmed: 34125947

open access

Online first
Original article
Published online: 2021-06-14

Abstract

Background: Research on the resorbable magnesium scaffolds (RMSs) has shown their safety and effectiveness in stable clinical conditions. It seems that this new therapeutic option could be promising for selected acute coronary syndrome (ACS) patients.

Aims: Our analysis aims to analyse the long-term performance of RMSs among ACS patients.

Methods: The study population consisted of consecutive ACS patients treated with the implantation of at least one RMS. The Magmaris ACS Registry was designed as a single-arm observational registry in the 'real-world' treatment practice setting.

Results: The study population consisted of 193 patients, predominantly male (78%), at a mean (SD) age of 64 (9) years and with the typical risk factors of ACS. Unstable angina (UA) was the indication for revascularisation in 32.1%, non-ST-segment myocardial infarction (NSTEMI) in 65.8% and ST-segment elevation myocardial infarction (STEMI) only in 2.1%. During the mean 24 months of follow-up, ten cases (5.2%) of target lesion failure (TLF) were diagnosed, of which five cases (2.6%) were clinically driven target lesion failure (CD-TLR), four cases (2.1%) of asymptomatic scaffold restenosis and one case (0.5%) of target vessel myocardial infarction (TV-MI). No cardiac deaths and 2 non-cardiac deaths (2.2%, both fatal strokes) were observed. No cases of scaffold thrombosis were observed during the median 24-month follow-up.

Conclusions: The use of the RMSs in selected ACS patients is associated with procedural safety and promising early and long-term clinical efficacy and safety outcomes. Proper lesion selection is key to the long-term success of bioresorbable technology in this patient population

Abstract

Background: Research on the resorbable magnesium scaffolds (RMSs) has shown their safety and effectiveness in stable clinical conditions. It seems that this new therapeutic option could be promising for selected acute coronary syndrome (ACS) patients.

Aims: Our analysis aims to analyse the long-term performance of RMSs among ACS patients.

Methods: The study population consisted of consecutive ACS patients treated with the implantation of at least one RMS. The Magmaris ACS Registry was designed as a single-arm observational registry in the 'real-world' treatment practice setting.

Results: The study population consisted of 193 patients, predominantly male (78%), at a mean (SD) age of 64 (9) years and with the typical risk factors of ACS. Unstable angina (UA) was the indication for revascularisation in 32.1%, non-ST-segment myocardial infarction (NSTEMI) in 65.8% and ST-segment elevation myocardial infarction (STEMI) only in 2.1%. During the mean 24 months of follow-up, ten cases (5.2%) of target lesion failure (TLF) were diagnosed, of which five cases (2.6%) were clinically driven target lesion failure (CD-TLR), four cases (2.1%) of asymptomatic scaffold restenosis and one case (0.5%) of target vessel myocardial infarction (TV-MI). No cardiac deaths and 2 non-cardiac deaths (2.2%, both fatal strokes) were observed. No cases of scaffold thrombosis were observed during the median 24-month follow-up.

Conclusions: The use of the RMSs in selected ACS patients is associated with procedural safety and promising early and long-term clinical efficacy and safety outcomes. Proper lesion selection is key to the long-term success of bioresorbable technology in this patient population

Get Citation

Keywords

resorbable magnesium scaffolds, acute coronary syndrome, long-term outcome

About this article
Title

Long-term clinical follow-up of the resorbable magnesium scaffolds in acute coronary syndrome patients

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Original article

Published online

2021-06-14

DOI

10.33963/KP.a2021.0035

Pubmed

34125947

Keywords

resorbable magnesium scaffolds
acute coronary syndrome
long-term outcome

Authors

Adrian Włodarczak
Magdalena Łanocha
Maciej Lesiak
Johan Benett
Marek Szudrowicz
Artur Jastrzębski
Maciej Pęcherzewski
Jan Jakub Kulczycki
Łukasz Furtan
Karol Turkiewicz
Andrzej Korda

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl